<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265144</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/42</org_study_id>
    <nct_id>NCT04265144</nct_id>
  </id_info>
  <brief_title>Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre</brief_title>
  <acronym>SCLERESO</acronym>
  <official_title>Cohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by&#xD;
      vascular involvement and the intensity of fibrosis. The lack of available treatment is&#xD;
      largely due to the very fragmented understanding of the pathophysiology of SSc. However, one&#xD;
      of the keys to conducting quality research on this disease remains the development of&#xD;
      well-documented patient cohorts with reliable biological samples. The main objective of this&#xD;
      cohort is to study the natural progression of SSc in a cohort of patients followed over 5&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by&#xD;
      vascular involvement and the intensity of fibrosis. Its prevalence and incidence are&#xD;
      difficult to assess, however, in France, a population survey conducted in Seine-St-Denis&#xD;
      calculated a prevalence of 161 cases per million inhabitants.&#xD;
&#xD;
      The pathophysiology of SSc, the exact etiology of which remains unknown, involves an&#xD;
      interaction between genetic and environmental factors. Its evolution can impact the&#xD;
      aesthetic, functional and even vital prognosis of the affected patient.Within the analysis of&#xD;
      SSc pathophysiology, a &quot; very early systemic sclerosis &quot; form of disease has been defined&#xD;
      according to the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN&#xD;
      positivity (≥1/160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity).&#xD;
&#xD;
      At present, no treatment to control this disease is available. The lack of available&#xD;
      treatment is largely due to the very fragmented understanding of the pathophysiology of SSc.&#xD;
      However, one of the keys to research remains the development of well-documented patient&#xD;
      cohorts with quality biological samples. The investigators had the opportunity to start a&#xD;
      major work on this plan with the VISS study (Vasculopathy and Inflammation in Systemic&#xD;
      Scleroderma study) in 2012 as part of a project promoted by the University Hospital of&#xD;
      Bordeaux (NCT02562079). This project has paved the way for many local, national and&#xD;
      international collaborations. It has made it possible to structure and federate various&#xD;
      partners of the Bordeaux University Hospital around translational research on SSc.&#xD;
&#xD;
      The investigators wish to continue our research and collaborations by further strengthening&#xD;
      our expertise in the collection of rare and valuable biological samples for this disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the main clinical characteristics of scleroderma patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
    <description>Worsening of the SSc according to the onset of a renal crisis (according to arterial hypertension &gt; 150/85 mm Hg ), a pulmonary arterial hypertension (identified with a right heart catheterization), or an interstitial lung disease (identified with a chest CT-scan).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of pulmonary arterial hypertension diagnosis in SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of interstitial lung disease diagnosis in SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of renal crisis diagnosis in SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Rodnan score for the evaluation of disease activity for SSc patients, with higher values mean higher disease activity.</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
    <description>(Min value: 0 - Max value: 51)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Diffusing capacity (DLCO) for the evaluation of disease activity for SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Forced vital capacity (FVC) for the evaluation of disease activity for SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of therapeutic strategies set up for SSc patients</measure>
    <time_frame>At baseline (Day 0) and 60 months after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Scleroderma</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Skin biopsies</description>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bronchoalveolar samples</intervention_name>
    <description>50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration</description>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Patient with systemic scleroderma according to the ACR/EULAR 2013 criteria, or with a&#xD;
             &quot; very early systemic sclerosis &quot; defined by the presence of Raynaud's phenomenon and&#xD;
             auto-antibodies in blood sample (ACAN positivity (≥1/160) with anti-Scl70,&#xD;
             anti-centromere or anti-ARNPolIII specificity).&#xD;
&#xD;
          -  Person affiliated or benefiting from a social security scheme.&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant and the investigator (no&#xD;
             later than the day of inclusion and prior to any review required by the research)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient under guardianship, curatorship or any other legal protection regime&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elise TRUCHETET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Elise TRUCHETET, MD, PhD</last_name>
    <phone>05.56.79.55.56</phone>
    <phone_ext>+33</phone_ext>
    <email>marie-elise.truchetet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas BARNETCHE, PhD</last_name>
    <phone>05.57.82.04.93</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.barnetche@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de rhumatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Elise TRUCHETET, MD, PhD</last_name>
      <phone>05.56.79.55.56</phone>
      <phone_ext>+33</phone_ext>
      <email>marie-elise.truchetet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas BARNETCHE, PhD</last_name>
      <phone>05.57.82.04.93</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.barnetche@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel CONSTANS, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien SENESCHAL, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie BLANCHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois PICARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DUFFAU, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cohort study</keyword>
  <keyword>systemic sclerosis</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

